CEACAM5 and neoplasm: In-depth N-glycan profiling indicates that α2,3-sialylation is down-regulated in CRC tumours relative to non-tumorigenic tissues33; therefore, tumour cells may have incomplete α2,3-sialylated glycans of CEA, such as asialo-type 5G2 mAb antigen.